Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $105,924.00 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $1,024.09 on Friday. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average price is $992.50 and its two-hundred day moving average price is $954.60. The firm has a market capitalization of $112.84 billion, a price-to-earnings ratio of 30.25, a P/E/G ratio of 2.12 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 12-month low of $688.52 and a 12-month high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on REGN. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Argus boosted their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Truist Financial restated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in REGN. Schonfeld Strategic Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 344.4% in the third quarter. Schonfeld Strategic Advisors LLC now owns 4,035 shares of the biopharmaceutical company’s stock valued at $3,321,000 after purchasing an additional 3,127 shares during the last quarter. JT Stratford LLC grew its position in shares of Regeneron Pharmaceuticals by 35.1% in the third quarter. JT Stratford LLC now owns 1,471 shares of the biopharmaceutical company’s stock valued at $1,211,000 after purchasing an additional 382 shares during the last quarter. Seven Eight Capital LP acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $802,000. Sectoral Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 16.4% during the third quarter. Sectoral Asset Management Inc. now owns 3,720 shares of the biopharmaceutical company’s stock worth $3,061,000 after buying an additional 524 shares in the last quarter. Finally, Scotia Capital Inc. acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $242,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.